老年HER2阳性早期乳腺癌:曲妥珠单抗单药对比联合化疗的随机对照试验
该开放标签随机对照研究纳入275例70-80岁术后HER2阳性早期乳腺癌患者,比较曲妥珠单抗单药与联合化疗。主要终点无病生存期(DFS)的非劣效性未达到,但3年生存损失小于1个月,且单药组毒性更低、健康相关生活质量更优。
要点
- 曲妥珠单抗单药3年DFS 89.5% vs 联合化疗93.8%,HR 1.36,非劣效性未达到。
- 单药组3/4级非血液学不良事件11.9% vs 联合组29.8%,毒性显著更低。
- 单药组生活质量恶化率在2个月和1年时均显著低于联合组。
核心结论
- 曲妥珠单抗单药对比联合化疗的非劣效性主要目标未达到,但3年生存损失小于1个月,且毒性更低、生活质量更优,可考虑作为部分老年患者的辅助治疗选择。
研究设计与样本
- 开放标签随机对照研究,采用治疗选择设计并预设非劣效性标准;纳入275例70-80岁术后HER2阳性侵袭性乳腺癌患者,平均年龄73.5岁,平均随访4.1年(范围0.3-8.0年)。
关键数值与推荐
- 分期构成:I期(pT>0.5 cm)43.6%,IIA期41.7%,IIB期13.5%,IIIA期1.1%。
- 非劣效性主要终点未达到,但3年生存损失<1个月。
临床怎么用
- 对于选定的老年HER2阳性早期乳腺癌患者,曲妥珠单抗单药可作为辅助治疗选项,需权衡生存获益与毒性及生活质量。
局限性
- 非劣效性未达到,生存获益略低于联合化疗;研究为开放标签设计;样本量275例,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adjuvant trastuzumab monotherapy has not been compared with trastuzumab + chemotherapy. We investigated the relative value of trastuzumab monotherapy for older patients with breast cancer. METHODS: This study was an open-label, randomized controlled study with a treatment selection design in which a noninferiority criterion was predefined. Patients aged 70-80 years with surgically treated human epidermal growth factor receptor 2-positive invasive breast cancer received trastuzumab monotherapy or trastuzumab + chemotherapy. The primary end point was disease-free survival (DFS) with assessment of prespecified hazard ratio (HR), relapse-free survival (RFS), adverse events (AEs), health-related quality of life (HRQoL), and restricted mean survival time (RMST). RESULTS: The study involved 275 patients (mean age, 73.5 years) who were followed up for a mean of 4.1 years (range, 0.3-8.0 years). The percentages of patients by cancer stage were as follows: I (pT > 0.5 cm), 43.6%; IIA, 41.7%; IIB, 13.5%; and IIIA, 1.1%. Three-year DFS was 89.5% with trastuzumab monotherapy versus 93.8% with trastuzumab + chemotherapy (HR, 1.36; 95% CI, 0.72 to 2.58; P = .51). At 3 years, RMST differed by -0.39 months between arms (95% CI, -1.71 to 0.93; P = .56). Three-year RFS was 92.4% with trastuzumab monotherapy versus 95.3% with trastuzumab + chemotherapy (HR, 1.33; 95% CI, 0.63 to 2.79; P = .53). Common AEs were anorexia (7.4% v 44.3%; P < .0001) and alopecia (2.2% v 71.7%; P < .0001), and grade 3/4 nonhematologic AEs occurred in 11.9% versus 29.8% (P = .0003) for trastuzumab monotherapy versus trastuzumab + chemotherapy, respectively. Clinically meaningful HRQoL deterioration rate showed significant differences at 2 months (31% for trastuzumab monotherapy v 48% for trastuzumab + chemotherapy; P = .016) and at 1 year (19% v 38%; P = .009). CONCLUSION: The primary objective of noninferiority for trastuzumab monotherapy was not met. However, the observed loss of survival without chemotherapy was < 1 month at 3 years. Therefore, and in light of the lower toxicity and more favorable HRQoL profile, trastuzumab monotherapy can be considered an adjuvant therapy option for selected older patients.
引用
- Sawaki M, Taira N, Uemura Y, et al. Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. J Clin Oncol. 2020. PMID: 32936713. doi:10.1200/JCO.20.00184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。